Phase II trial of 10-deaza-aminopterin in patients with advanced colorectal cancer.
Twenty-two patients with advanced colorectal cancer were treated with 10-deaza-aminopterin given intravenously twice weekly for four doses beginning at 15 mg/m2. Twelve patients had no prior chemotherapy. Dose-limiting toxicity was mucositis. Tumor regression was not seen in any patient.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000630:Aminopterin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000630:Aminopterin; C017178:10-deazaaminopterin